Know Cancer

forgot password

A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

Phase 2
18 Years
Open (Enrolling)
Metastatic Uveal Melanoma

Thank you

Trial Information

A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

124 eligible patients will be randomised to either Sunitinib or Dacarbazine treatment.
Participants will then attend 3-weekly clinic visits and undergo 12-weekly tumour assessment
(CT or MRI scan) until disease progression (according to RECIST 1.1) has been identified.

At progression, patients may crossover to the other study treatment and continue with
3-weekly clinic visits and 12-weekly imaging until second progression.

Inclusion Criteria:

- Patients with histologically or cytologically confirmed unresectable, metastatic
uveal melanoma (histology must be available from a metastatic site)

- Patients with disease that is not amenable to surgery, radiation, or combined
modality therapy with curative intent No prior systemic therapy for advanced disease,
including regional delivery of drug therapy (prior surgery or radiofrequency ablation
is acceptable)

- Patients who have received prior radiotherapy are eligible, however, measurable
lesions must not have been previously irradiated

- Life expectancy > 12 weeks ECOG Performance status 0, 1 or 2

- At least one measurable target lesion, for further evaluation according to the
Response Evaluation Criteria In Solid Tumours - RECIST version 1.1 completed within
28 days of randomisation

- Aged > 18 years

- Adequate haematological, renal and liver function as defined below and performed
within 14 days of study inclusion:

Hb > 10 g/dl, platelets > 100 x109/L, WCC > 3.0 x109/L, ANC > 1.5x109/L, Bili < 1.5 x ULN,
Alk phos < 5 x ULN, transaminases < 5 x ULN, Cr < 1.5 x ULN

- Able to provide written informed consent

- Females of child-bearing potential who have a negative pregnancy test prior to study
entry and be using adequate contraception, which they agree to continue for 12 months
after the study treatment

Exclusion Criteria:

Patients who have:

- Conjunctival melanoma

- Received any previous systemic therapy for uveal melanoma

- Known leptomeningeal or brain metastases

- Patients with a history of prior malignant disease (unless they have had more than 3
years free of disease or have had adequately treated non-melanomatous skin cancer or
in situ carcinoma of the cervix)

- Had treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days
respectively, prior to study treatment administration

- Therapeutic anticoagulation for treatment of DVT/PE. Concomitant treatment with
therapeutic doses of anticoagulants (low dose warfarin up to 2mg PO daily for deep
vein thrombosis prophylaxis is allowed)

- Unstable systemic diseases including uncontrolled hypertension (>150/100 mmHg despite
optimal medical therapy) or active uncontrolled infections

- Any of the following within the 6 months prior to study drug administration:
myocardial infarction, severe/unstable angina, symptomatic congestive heart failure,
cerebrovascular accident or transient ischemic attack, or pulmonary embolism

- Clinically significant abnormal cardiac function with abnormal 12 lead ECG. Ongoing
cardiac dysrhythmias of NCI CTCAE grade 2, poorly controlled atrial fibrillation of
any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec
for females

- Any other serious or uncontrolled illness which, in the opinion of the investigator,
makes it undesirable for the patient to enter the trial

- Any medical or psychiatric condition which would influence the ability to provide
informed consent

- Pregnant or lactating women Lack of informed consent

- Any previous investigational agent within the last 12 weeks

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival

Outcome Description:

The primary outcome measure for this trial is the progression-free survival time measured from date of randomisation. For patients with evidence of progressive disease (as measured by CT scan, or MRI if necessary) or patients who have died from any cause, progression-free survival time will be calculated to date of progressive disease or date of death (whichever occurs first) and will be counted as events in the analysis. Patients still alive with no evidence of progression at the time of their last visit are censored at the time of the most recent information.

Outcome Time Frame:

Once all patients have been followed up for at least 3 months

Safety Issue:


Principal Investigator

Ernest Marshall

Investigator Role:

Principal Investigator

Investigator Affiliation:

Clatterbridge Centre for Oncology NHS Foundation Trust


United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:




Start Date:

October 2010

Completion Date:

April 2014

Related Keywords:

  • Metastatic Uveal Melanoma
  • Uveal
  • Melanoma
  • Metastatic
  • Sunitinib
  • Melanoma
  • Uveal Neoplasms